Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9

The capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expr...

Full description

Bibliographic Details
Main Authors: Jonathan Dashkoff, Eli P Lerner, Nhi Truong, Jacob A Klickstein, Zhanyun Fan, Dakai Mu, Casey A Maguire, Bradley T Hyman, Eloise Hudry
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050117300396
id doaj-268aaa1355464350a8486123556bc6b4
record_format Article
spelling doaj-268aaa1355464350a8486123556bc6b42020-11-24T23:48:03ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012016-01-013C10.1038/mtm.2016.81Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9Jonathan Dashkoff0Eli P Lerner1Nhi Truong2Jacob A Klickstein3Zhanyun Fan4Dakai Mu5Casey A Maguire6Bradley T Hyman7Eloise Hudry8Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USADepartment of Neurology, The Massachusetts General Hospital, and NeuroDiscovery Center, Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, The Massachusetts General Hospital, and NeuroDiscovery Center, Harvard Medical School, Boston, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAMassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USAThe capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expression in nontarget cells or organs. To refine this approach, the present study characterizes the transduction profiles of new self-complementary AAV9 (scAAV9) expressing the green fluorescent protein (GFP) either under an astrocyte (glial fibrillary acidic (GFA) protein) or neuronal (Synapsin (Syn)) promoter, after intravenous injection of adult mice (2 × 1013 vg/kg). ScAAV9-GFA-GFP and scAAV9-Syn-GFP robustly transduce astrocytes (11%) and neurons (17%), respectively, without aberrant expression leakage. Interestingly, while the percentages of GFP-positive astrocytes with scAAV9-GFA-GFP are similar to the performances observed with scAAV9-CBA-GFP (broadly active promoter), significant higher percentages of neurons express GFP with scAAV9-Syn-GFP. GFP-positive excitatory as well as inhibitory neurons are observed, as well as motor neurons in the spinal cord. Additionally, both activated (GFAP-positive) and resting astrocytes (GFAP-negative) express the reporter gene after scAAV9-GFA-GFP injection. These data thoroughly characterize the gene expression specificity of AAVs fitted with neuronal and astrocyte-selective promoters after intravenous delivery, which will prove useful for central nervous system (CNS) gene therapy approaches in which peripheral expression of transgene is a concern.http://www.sciencedirect.com/science/article/pii/S2329050117300396
collection DOAJ
language English
format Article
sources DOAJ
author Jonathan Dashkoff
Eli P Lerner
Nhi Truong
Jacob A Klickstein
Zhanyun Fan
Dakai Mu
Casey A Maguire
Bradley T Hyman
Eloise Hudry
spellingShingle Jonathan Dashkoff
Eli P Lerner
Nhi Truong
Jacob A Klickstein
Zhanyun Fan
Dakai Mu
Casey A Maguire
Bradley T Hyman
Eloise Hudry
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
Molecular Therapy: Methods & Clinical Development
author_facet Jonathan Dashkoff
Eli P Lerner
Nhi Truong
Jacob A Klickstein
Zhanyun Fan
Dakai Mu
Casey A Maguire
Bradley T Hyman
Eloise Hudry
author_sort Jonathan Dashkoff
title Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
title_short Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
title_full Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
title_fullStr Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
title_full_unstemmed Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9
title_sort tailored transgene expression to specific cell types in the central nervous system after peripheral injection with aav9
publisher Elsevier
series Molecular Therapy: Methods & Clinical Development
issn 2329-0501
publishDate 2016-01-01
description The capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expression in nontarget cells or organs. To refine this approach, the present study characterizes the transduction profiles of new self-complementary AAV9 (scAAV9) expressing the green fluorescent protein (GFP) either under an astrocyte (glial fibrillary acidic (GFA) protein) or neuronal (Synapsin (Syn)) promoter, after intravenous injection of adult mice (2 × 1013 vg/kg). ScAAV9-GFA-GFP and scAAV9-Syn-GFP robustly transduce astrocytes (11%) and neurons (17%), respectively, without aberrant expression leakage. Interestingly, while the percentages of GFP-positive astrocytes with scAAV9-GFA-GFP are similar to the performances observed with scAAV9-CBA-GFP (broadly active promoter), significant higher percentages of neurons express GFP with scAAV9-Syn-GFP. GFP-positive excitatory as well as inhibitory neurons are observed, as well as motor neurons in the spinal cord. Additionally, both activated (GFAP-positive) and resting astrocytes (GFAP-negative) express the reporter gene after scAAV9-GFA-GFP injection. These data thoroughly characterize the gene expression specificity of AAVs fitted with neuronal and astrocyte-selective promoters after intravenous delivery, which will prove useful for central nervous system (CNS) gene therapy approaches in which peripheral expression of transgene is a concern.
url http://www.sciencedirect.com/science/article/pii/S2329050117300396
work_keys_str_mv AT jonathandashkoff tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT eliplerner tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT nhitruong tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT jacobaklickstein tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT zhanyunfan tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT dakaimu tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT caseyamaguire tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT bradleythyman tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
AT eloisehudry tailoredtransgeneexpressiontospecificcelltypesinthecentralnervoussystemafterperipheralinjectionwithaav9
_version_ 1725487500923764736